Amgen’s Phase III data supports FDA label expansion of Repatha
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
India currently hosts more than 10,075 biotech startups
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Subscribe To Our Newsletter & Stay Updated